nodes	percent_of_prediction	percent_of_DWPC	metapath
Omeprazole—CYP2C18—Xenobiotics—CYP2A7—nicotine dependence	0.0168	0.0581	CbGpPWpGaD
Omeprazole—Urine abnormality—Varenicline—nicotine dependence	0.0167	0.0235	CcSEcCtD
Omeprazole—Sleep disturbance—Varenicline—nicotine dependence	0.0165	0.0232	CcSEcCtD
Omeprazole—Urine analysis abnormal—Varenicline—nicotine dependence	0.0157	0.0221	CcSEcCtD
Omeprazole—Parosmia—Varenicline—nicotine dependence	0.0143	0.0201	CcSEcCtD
Omeprazole—Cyst—Varenicline—nicotine dependence	0.0138	0.0195	CcSEcCtD
Omeprazole—Menstrual disorder—Varenicline—nicotine dependence	0.0136	0.0191	CcSEcCtD
Omeprazole—Scotoma—Varenicline—nicotine dependence	0.0122	0.0171	CcSEcCtD
Omeprazole—Fungal infection—Varenicline—nicotine dependence	0.012	0.0168	CcSEcCtD
Omeprazole—Glycosuria—Varenicline—nicotine dependence	0.0114	0.0161	CcSEcCtD
Omeprazole—CYP2C8—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0113	0.039	CbGpPWpGaD
Omeprazole—Eye irritation—Varenicline—nicotine dependence	0.0108	0.0152	CcSEcCtD
Omeprazole—Aggression—Varenicline—nicotine dependence	0.0105	0.0148	CcSEcCtD
Omeprazole—Accidental injury—Varenicline—nicotine dependence	0.0104	0.0147	CcSEcCtD
Omeprazole—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.0102	0.0144	CcSEcCtD
Omeprazole—ATP4B—Ion channel transport—GABRA4—nicotine dependence	0.0102	0.0351	CbGpPWpGaD
Omeprazole—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0101	0.0348	CbGpPWpGaD
Omeprazole—Leukocytosis—Varenicline—nicotine dependence	0.00984	0.0138	CcSEcCtD
Omeprazole—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00926	0.032	CbGpPWpGaD
Omeprazole—Blood pressure increased—Varenicline—nicotine dependence	0.00925	0.013	CcSEcCtD
Omeprazole—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00918	0.0317	CbGpPWpGaD
Omeprazole—Eructation—Varenicline—nicotine dependence	0.00908	0.0128	CcSEcCtD
Omeprazole—ATP4A—Ion channel transport—GABRA4—nicotine dependence	0.00905	0.0313	CbGpPWpGaD
Omeprazole—Dry eye—Varenicline—nicotine dependence	0.00854	0.012	CcSEcCtD
Omeprazole—Oesophagitis—Varenicline—nicotine dependence	0.00845	0.0119	CcSEcCtD
Omeprazole—Mouth ulceration—Varenicline—nicotine dependence	0.00836	0.0118	CcSEcCtD
Omeprazole—Urine output increased—Varenicline—nicotine dependence	0.00836	0.0118	CcSEcCtD
Omeprazole—Hypertonia—Varenicline—nicotine dependence	0.0081	0.0114	CcSEcCtD
Omeprazole—CYP11A1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00806	0.0279	CbGpPWpGaD
Omeprazole—CYP11A1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00795	0.0275	CbGpPWpGaD
Omeprazole—Lymphadenopathy—Varenicline—nicotine dependence	0.00787	0.0111	CcSEcCtD
Omeprazole—Sleep disorder—Varenicline—nicotine dependence	0.00775	0.0109	CcSEcCtD
Omeprazole—Polyuria—Varenicline—nicotine dependence	0.00764	0.0108	CcSEcCtD
Omeprazole—CYP1A1—Xenobiotics—CYP2A7—nicotine dependence	0.00762	0.0264	CbGpPWpGaD
Omeprazole—Injury—Varenicline—nicotine dependence	0.0073	0.0103	CcSEcCtD
Omeprazole—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00722	0.025	CbGpPWpGaD
Omeprazole—Hot flush—Varenicline—nicotine dependence	0.00717	0.0101	CcSEcCtD
Omeprazole—Increased appetite—Varenicline—nicotine dependence	0.00714	0.01	CcSEcCtD
Omeprazole—Menopausal symptoms—Varenicline—nicotine dependence	0.00711	0.01	CcSEcCtD
Omeprazole—Visual disturbance—Varenicline—nicotine dependence	0.00708	0.00996	CcSEcCtD
Omeprazole—Thirst—Varenicline—nicotine dependence	0.00705	0.00992	CcSEcCtD
Omeprazole—CYP2C8—Xenobiotics—CYP2A7—nicotine dependence	0.00699	0.0242	CbGpPWpGaD
Omeprazole—CYP2C18—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00697	0.0241	CbGpPWpGaD
Omeprazole—Arthritis—Varenicline—nicotine dependence	0.0069	0.00971	CcSEcCtD
Omeprazole—CYP2C18—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00688	0.0238	CbGpPWpGaD
Omeprazole—Hypoglycaemia—Varenicline—nicotine dependence	0.00688	0.00967	CcSEcCtD
Omeprazole—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.00671	0.00944	CcSEcCtD
Omeprazole—Osteoarthritis—Varenicline—nicotine dependence	0.00671	0.00944	CcSEcCtD
Omeprazole—Migraine—Varenicline—nicotine dependence	0.00661	0.00929	CcSEcCtD
Omeprazole—CYP11A1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00653	0.0226	CbGpPWpGaD
Omeprazole—Irritability—Varenicline—nicotine dependence	0.00641	0.00901	CcSEcCtD
Omeprazole—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.00624	0.0216	CbGpPWpGaD
Omeprazole—Dry skin—Varenicline—nicotine dependence	0.00615	0.00865	CcSEcCtD
Omeprazole—Abdominal pain upper—Varenicline—nicotine dependence	0.00613	0.00862	CcSEcCtD
Omeprazole—Hypokalaemia—Varenicline—nicotine dependence	0.00611	0.00859	CcSEcCtD
Omeprazole—Breast disorder—Varenicline—nicotine dependence	0.00606	0.00853	CcSEcCtD
Omeprazole—Cramp muscle—Varenicline—nicotine dependence	0.00604	0.0085	CcSEcCtD
Omeprazole—Gastritis—Varenicline—nicotine dependence	0.00594	0.00836	CcSEcCtD
Omeprazole—Abdominal distension—Varenicline—nicotine dependence	0.00584	0.00821	CcSEcCtD
Omeprazole—Asthma—Varenicline—nicotine dependence	0.0058	0.00816	CcSEcCtD
Omeprazole—Dysphagia—Varenicline—nicotine dependence	0.0058	0.00816	CcSEcCtD
Omeprazole—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00574	0.0198	CbGpPWpGaD
Omeprazole—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.00569	0.0197	CbGpPWpGaD
Omeprazole—CYP2C18—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00565	0.0195	CbGpPWpGaD
Omeprazole—Angina pectoris—Varenicline—nicotine dependence	0.00565	0.00795	CcSEcCtD
Omeprazole—Pollakiuria—Varenicline—nicotine dependence	0.00536	0.00754	CcSEcCtD
Omeprazole—Erectile dysfunction—Varenicline—nicotine dependence	0.00534	0.00752	CcSEcCtD
Omeprazole—Photosensitivity reaction—Varenicline—nicotine dependence	0.00529	0.00745	CcSEcCtD
Omeprazole—Weight increased—Varenicline—nicotine dependence	0.00528	0.00743	CcSEcCtD
Omeprazole—Infestation—Varenicline—nicotine dependence	0.00517	0.00728	CcSEcCtD
Omeprazole—Infestation NOS—Varenicline—nicotine dependence	0.00517	0.00728	CcSEcCtD
Omeprazole—Depression—Varenicline—nicotine dependence	0.00516	0.00725	CcSEcCtD
Omeprazole—CYP1B1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00514	0.0178	CbGpPWpGaD
Omeprazole—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00513	0.00721	CcSEcCtD
Omeprazole—CYP1B1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00507	0.0175	CbGpPWpGaD
Omeprazole—Stomatitis—Varenicline—nicotine dependence	0.00504	0.00709	CcSEcCtD
Omeprazole—Conjunctivitis—Varenicline—nicotine dependence	0.00503	0.00707	CcSEcCtD
Omeprazole—Hepatobiliary disease—Varenicline—nicotine dependence	0.00489	0.00688	CcSEcCtD
Omeprazole—Epistaxis—Varenicline—nicotine dependence	0.00488	0.00686	CcSEcCtD
Omeprazole—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00486	0.0168	CbGpPWpGaD
Omeprazole—Sinusitis—Varenicline—nicotine dependence	0.00485	0.00683	CcSEcCtD
Omeprazole—Bradycardia—Varenicline—nicotine dependence	0.00473	0.00665	CcSEcCtD
Omeprazole—Hypoaesthesia—Varenicline—nicotine dependence	0.00462	0.0065	CcSEcCtD
Omeprazole—Hallucination—Varenicline—nicotine dependence	0.00462	0.0065	CcSEcCtD
Omeprazole—Urinary tract disorder—Varenicline—nicotine dependence	0.00458	0.00645	CcSEcCtD
Omeprazole—Oedema peripheral—Varenicline—nicotine dependence	0.00457	0.00643	CcSEcCtD
Omeprazole—Connective tissue disorder—Varenicline—nicotine dependence	0.00456	0.00642	CcSEcCtD
Omeprazole—Urethral disorder—Varenicline—nicotine dependence	0.00455	0.0064	CcSEcCtD
Omeprazole—Visual impairment—Varenicline—nicotine dependence	0.00447	0.00629	CcSEcCtD
Omeprazole—Erythema multiforme—Varenicline—nicotine dependence	0.00439	0.00618	CcSEcCtD
Omeprazole—Eye disorder—Varenicline—nicotine dependence	0.00434	0.0061	CcSEcCtD
Omeprazole—Tinnitus—Varenicline—nicotine dependence	0.00433	0.00609	CcSEcCtD
Omeprazole—Immune system disorder—Varenicline—nicotine dependence	0.00419	0.0059	CcSEcCtD
Omeprazole—Mediastinal disorder—Varenicline—nicotine dependence	0.00418	0.00589	CcSEcCtD
Omeprazole—CYP1B1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00417	0.0144	CbGpPWpGaD
Omeprazole—Chills—Varenicline—nicotine dependence	0.00417	0.00586	CcSEcCtD
Omeprazole—Mental disorder—Varenicline—nicotine dependence	0.00407	0.00572	CcSEcCtD
Omeprazole—Malnutrition—Varenicline—nicotine dependence	0.00404	0.00569	CcSEcCtD
Omeprazole—Flatulence—Varenicline—nicotine dependence	0.00398	0.0056	CcSEcCtD
Omeprazole—Dysgeusia—Varenicline—nicotine dependence	0.00396	0.00557	CcSEcCtD
Omeprazole—Back pain—Varenicline—nicotine dependence	0.00391	0.0055	CcSEcCtD
Omeprazole—Muscle spasms—Varenicline—nicotine dependence	0.00389	0.00547	CcSEcCtD
Omeprazole—Vision blurred—Varenicline—nicotine dependence	0.00381	0.00536	CcSEcCtD
Omeprazole—Tremor—Varenicline—nicotine dependence	0.00379	0.00533	CcSEcCtD
Omeprazole—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00375	0.013	CbGpPWpGaD
Omeprazole—Ill-defined disorder—Varenicline—nicotine dependence	0.00375	0.00528	CcSEcCtD
Omeprazole—Anaemia—Varenicline—nicotine dependence	0.00374	0.00526	CcSEcCtD
Omeprazole—Agitation—Varenicline—nicotine dependence	0.00371	0.00523	CcSEcCtD
Omeprazole—Angioedema—Varenicline—nicotine dependence	0.00369	0.0052	CcSEcCtD
Omeprazole—CYP11A1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00368	0.0127	CbGpPWpGaD
Omeprazole—Malaise—Varenicline—nicotine dependence	0.00364	0.00513	CcSEcCtD
Omeprazole—Vertigo—Varenicline—nicotine dependence	0.00363	0.00511	CcSEcCtD
Omeprazole—Palpitations—Varenicline—nicotine dependence	0.00357	0.00502	CcSEcCtD
Omeprazole—ATP4B—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00353	0.0122	CbGpPWpGaD
Omeprazole—Cough—Varenicline—nicotine dependence	0.00353	0.00496	CcSEcCtD
Omeprazole—Hypertension—Varenicline—nicotine dependence	0.00349	0.00491	CcSEcCtD
Omeprazole—CYP11A1—Biological oxidations—CYP2A7—nicotine dependence	0.00347	0.012	CbGpPWpGaD
Omeprazole—Chest pain—Varenicline—nicotine dependence	0.00344	0.00484	CcSEcCtD
Omeprazole—Myalgia—Varenicline—nicotine dependence	0.00344	0.00484	CcSEcCtD
Omeprazole—Arthralgia—Varenicline—nicotine dependence	0.00344	0.00484	CcSEcCtD
Omeprazole—Anxiety—Varenicline—nicotine dependence	0.00343	0.00482	CcSEcCtD
Omeprazole—CYP11A1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00342	0.0118	CbGpPWpGaD
Omeprazole—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00342	0.00481	CcSEcCtD
Omeprazole—Discomfort—Varenicline—nicotine dependence	0.0034	0.00478	CcSEcCtD
Omeprazole—Dry mouth—Varenicline—nicotine dependence	0.00336	0.00473	CcSEcCtD
Omeprazole—Infection—Varenicline—nicotine dependence	0.00328	0.00461	CcSEcCtD
Omeprazole—Shock—Varenicline—nicotine dependence	0.00325	0.00457	CcSEcCtD
Omeprazole—Nervous system disorder—Varenicline—nicotine dependence	0.00323	0.00455	CcSEcCtD
Omeprazole—Thrombocytopenia—Varenicline—nicotine dependence	0.00323	0.00454	CcSEcCtD
Omeprazole—Tachycardia—Varenicline—nicotine dependence	0.00322	0.00453	CcSEcCtD
Omeprazole—Skin disorder—Varenicline—nicotine dependence	0.0032	0.00451	CcSEcCtD
Omeprazole—Hyperhidrosis—Varenicline—nicotine dependence	0.00319	0.00449	CcSEcCtD
Omeprazole—CYP2C18—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00319	0.011	CbGpPWpGaD
Omeprazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00317	0.0109	CbGpPWpGaD
Omeprazole—ATP4A—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00315	0.0109	CbGpPWpGaD
Omeprazole—Anorexia—Varenicline—nicotine dependence	0.00314	0.00442	CcSEcCtD
Omeprazole—CYP1A1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00312	0.0108	CbGpPWpGaD
Omeprazole—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00301	0.00423	CcSEcCtD
Omeprazole—CYP2C18—Biological oxidations—CYP2A7—nicotine dependence	0.003	0.0104	CbGpPWpGaD
Omeprazole—Insomnia—Varenicline—nicotine dependence	0.00298	0.0042	CcSEcCtD
Omeprazole—CYP2C18—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00296	0.0102	CbGpPWpGaD
Omeprazole—Dyspnoea—Varenicline—nicotine dependence	0.00294	0.00414	CcSEcCtD
Omeprazole—Somnolence—Varenicline—nicotine dependence	0.00293	0.00413	CcSEcCtD
Omeprazole—Dyspepsia—Varenicline—nicotine dependence	0.0029	0.00408	CcSEcCtD
Omeprazole—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.0029	0.01	CbGpPWpGaD
Omeprazole—Decreased appetite—Varenicline—nicotine dependence	0.00287	0.00403	CcSEcCtD
Omeprazole—CYP2C8—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00286	0.0099	CbGpPWpGaD
Omeprazole—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00285	0.00401	CcSEcCtD
Omeprazole—Fatigue—Varenicline—nicotine dependence	0.00284	0.004	CcSEcCtD
Omeprazole—Pain—Varenicline—nicotine dependence	0.00282	0.00397	CcSEcCtD
Omeprazole—Constipation—Varenicline—nicotine dependence	0.00282	0.00397	CcSEcCtD
Omeprazole—Feeling abnormal—Varenicline—nicotine dependence	0.00272	0.00382	CcSEcCtD
Omeprazole—Gastrointestinal pain—Varenicline—nicotine dependence	0.0027	0.00379	CcSEcCtD
Omeprazole—Urticaria—Varenicline—nicotine dependence	0.00262	0.00369	CcSEcCtD
Omeprazole—Abdominal pain—Varenicline—nicotine dependence	0.00261	0.00367	CcSEcCtD
Omeprazole—Body temperature increased—Varenicline—nicotine dependence	0.00261	0.00367	CcSEcCtD
Omeprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00259	0.00896	CbGpPWpGaD
Omeprazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00257	0.00887	CbGpPWpGaD
Omeprazole—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00256	0.00884	CbGpPWpGaD
Omeprazole—Hypersensitivity—Varenicline—nicotine dependence	0.00243	0.00342	CcSEcCtD
Omeprazole—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00238	0.00824	CbGpPWpGaD
Omeprazole—Asthenia—Varenicline—nicotine dependence	0.00237	0.00333	CcSEcCtD
Omeprazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00236	0.00817	CbGpPWpGaD
Omeprazole—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00235	0.00814	CbGpPWpGaD
Omeprazole—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00235	0.00813	CbGpPWpGaD
Omeprazole—CYP1B1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00235	0.00812	CbGpPWpGaD
Omeprazole—Pruritus—Varenicline—nicotine dependence	0.00233	0.00328	CcSEcCtD
Omeprazole—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00233	0.00806	CbGpPWpGaD
Omeprazole—Diarrhoea—Varenicline—nicotine dependence	0.00226	0.00317	CcSEcCtD
Omeprazole—CYP1B1—Biological oxidations—CYP2A7—nicotine dependence	0.00221	0.00765	CbGpPWpGaD
Omeprazole—CYP1B1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00218	0.00755	CbGpPWpGaD
Omeprazole—Dizziness—Varenicline—nicotine dependence	0.00218	0.00307	CcSEcCtD
Omeprazole—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0021	0.00726	CbGpPWpGaD
Omeprazole—Vomiting—Varenicline—nicotine dependence	0.0021	0.00295	CcSEcCtD
Omeprazole—Rash—Varenicline—nicotine dependence	0.00208	0.00293	CcSEcCtD
Omeprazole—Dermatitis—Varenicline—nicotine dependence	0.00208	0.00292	CcSEcCtD
Omeprazole—Headache—Varenicline—nicotine dependence	0.00207	0.00291	CcSEcCtD
Omeprazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00202	0.00698	CbGpPWpGaD
Omeprazole—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00199	0.00689	CbGpPWpGaD
Omeprazole—Nausea—Varenicline—nicotine dependence	0.00196	0.00276	CcSEcCtD
Omeprazole—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00193	0.00668	CbGpPWpGaD
Omeprazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00191	0.00662	CbGpPWpGaD
Omeprazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00164	0.00566	CbGpPWpGaD
Omeprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00156	0.00539	CbGpPWpGaD
Omeprazole—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00154	0.00532	CbGpPWpGaD
Omeprazole—CYP1A1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00145	0.005	CbGpPWpGaD
Omeprazole—CYP1A1—Biological oxidations—CYP2A7—nicotine dependence	0.00136	0.00471	CbGpPWpGaD
Omeprazole—CYP1A1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00134	0.00465	CbGpPWpGaD
Omeprazole—CYP2C8—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00133	0.00458	CbGpPWpGaD
Omeprazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00126	0.00437	CbGpPWpGaD
Omeprazole—CYP2C8—Biological oxidations—CYP2A7—nicotine dependence	0.00125	0.00432	CbGpPWpGaD
Omeprazole—CYP2C8—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00123	0.00426	CbGpPWpGaD
Omeprazole—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00118	0.00409	CbGpPWpGaD
Omeprazole—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.00112	0.00386	CbGpPWpGaD
Omeprazole—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.0011	0.0038	CbGpPWpGaD
Omeprazole—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00109	0.00376	CbGpPWpGaD
Omeprazole—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00108	0.00373	CbGpPWpGaD
Omeprazole—ABCC3—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00107	0.00369	CbGpPWpGaD
Omeprazole—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.00103	0.00355	CbGpPWpGaD
Omeprazole—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.00102	0.00352	CbGpPWpGaD
Omeprazole—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00101	0.0035	CbGpPWpGaD
Omeprazole—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.001	0.00347	CbGpPWpGaD
Omeprazole—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000922	0.00319	CbGpPWpGaD
Omeprazole—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.000869	0.00301	CbGpPWpGaD
Omeprazole—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000857	0.00296	CbGpPWpGaD
Omeprazole—ABCG2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000735	0.00254	CbGpPWpGaD
Omeprazole—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000712	0.00246	CbGpPWpGaD
Omeprazole—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000671	0.00232	CbGpPWpGaD
Omeprazole—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000662	0.00229	CbGpPWpGaD
Omeprazole—CYP11A1—Metabolism—CYP2A7—nicotine dependence	0.000593	0.00205	CbGpPWpGaD
Omeprazole—CYP2C18—Metabolism—CYP2A7—nicotine dependence	0.000513	0.00178	CbGpPWpGaD
Omeprazole—ABCC3—Metabolism—CYP2A7—nicotine dependence	0.0005	0.00173	CbGpPWpGaD
Omeprazole—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000398	0.00137	CbGpPWpGaD
Omeprazole—CYP1B1—Metabolism—CYP2A7—nicotine dependence	0.000379	0.00131	CbGpPWpGaD
Omeprazole—ABCG2—Metabolism—CYP2A7—nicotine dependence	0.000344	0.00119	CbGpPWpGaD
Omeprazole—CYP1A1—Metabolism—CYP2A7—nicotine dependence	0.000233	0.000806	CbGpPWpGaD
Omeprazole—CYP2C8—Metabolism—CYP2A7—nicotine dependence	0.000214	0.000739	CbGpPWpGaD
Omeprazole—CYP2C19—Metabolism—CYP2A7—nicotine dependence	0.000191	0.00066	CbGpPWpGaD
Omeprazole—ABCB1—Metabolism—CYP2A7—nicotine dependence	0.000186	0.000644	CbGpPWpGaD
Omeprazole—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000175	0.000607	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000174	0.000601	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism—CYP2A7—nicotine dependence	0.000149	0.000514	CbGpPWpGaD
Omeprazole—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000115	0.000397	CbGpPWpGaD
